What role does a new mechanism of action play in your prescribing decisions of IBS-C therapy?

Thank you to Ardelyx for sponsoring this FAQ Video Module!

Join Kim Orleck, GHAPP member and Physician Assistant at Atlanta Gastroenterology Associates. In this FAQ, Kim discusses how new mechanisms of action influence her prescribing decisions for IBS-C therapy. She highlights the exciting introduction of a novel medication with a triple-action mechanism of action, which offers an alternative to the traditional secretagogues. Kim explains how this new therapy works by inhibiting the sodium-hydrogen exchanger, leading to increased luminal water content, reduced intestinal permeability, and decreased visceral hypersensitivity, ultimately addressing the multifactorial pathophysiology of IBS-C. For more information, visit ghapp.org.